Quest Diagnostics (DGX): are the analysts right?

Quest Diagnostics · Health Care · ref. ETF XLV · 51 calls · price $212.38
What the company does: Quest Diagnostics fournit des services de diagnostic et de tests cliniques aux États-Unis.
📈 1-year price
$212.38+23.1% over range
Jul 8, 25low $166.42 · high $216.02Jul 7, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
38% recommend buying · 8 analysts

🎯 Analyst price target on DGX

High target · 3 analysts$235+10.7%
Median target · 8 analysts$222.5+4.8%
Low target · 2 analysts$210-1.1%
Current price$212.38

🗳️ The analyst consensus

Analyst breakdown · 8 (6 months)
Strong Buy0%
Buy38%
Hold63%
Sell0%
Strong Sell0%

💰 Quest Diagnostics dividend

1.51%annual yield
📈 Steady dividend14 yrs of consecutive dividend increases
That's ~$3.26 per share per year.

✅ Historical analyst reliability on DGX

Most reliable analysts on DGX (% profitable · 365j · ≥2 calls)
Mizuho 100% +16.6% 4
Baird 100% +16.0% 2

📊 What $1,000 invested in Quest Diagnostics would be worth

In short — $1,000 invested in Quest Diagnostics 10 years ago would be worth $2,979 today, i.e. +12%/yr on average. Best year: 2021 (+45%), worst: 2018 (-15%). Price performance, excluding dividends.

If I'd invested $1,000 in Quest Diagnostics

InvestmentWorth todayGain
1 years ago$1,405+40%
3 years ago$1,355+35%
5 years ago$1,779+78%
10 years ago$2,979+198%
since inception (1997)$53,829+5283%

Return by year (Quest Diagnostics)

YearReturn$1,000 invested at year start
2026 (YTD)+22%$1,221 (+22%)
2025+15%$1,405 (+40%)
2024+9%$1,537 (+54%)
2023-12%$1,355 (+35%)
2022-10%$1,225 (+23%)
2021+45%$1,779 (+78%)
2020+12%$1,985 (+98%)
2019+28%$2,545 (+155%)
2018-15%$2,152 (+115%)
2017+7%$2,306 (+131%)
2016+29%$2,979 (+198%)
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

🔎 Detailed analyses

👥 Analysts & forecasts📊 Returns & performance💰 Dividend
📈 Fundamentals, technical momentum and live news will show here on the final site (loaded live from the same origin as the API).

📋 All analyst calls on DGX

UBS
Apr 22, 26
■ Neutral neutral · not a buy · 🎯$220
Price at call : $199.53 — gap to target +10%
Today : $212.38 — gap to target +4%
🎯 on DGX : no call matured yet · 📊 on Health : 52.1% · +3.4% (340 calls)
in progress (365j)
matures : Apr 22, 27
Baird
Apr 22, 26
■ Neutral neutral · not a buy · 🎯$229
Price at call : $204 — gap to target +12%
Today : $212.38 — gap to target +8%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 52.3% · +7.1% (287 calls)
in progress (365j)
matures : Apr 22, 27
Barclays
Apr 22, 26
▲ Overweight · 🎯$230
Price at call : $204 — upside +13%
Today : $212.38 — upside +8%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (617 calls)
in progress (365j)
matures : Apr 22, 27
■ Hold neutral · not a buy · 🎯$225
Price at call : $204 — gap to target +10%
Today : $212.38 — gap to target +6%
🎯 on DGX : no call matured yet · 📊 on Health : 50% · +2.1% (248 calls)
in progress (365j)
matures : Apr 22, 27
■ In-Line neutral · not a buy · 🎯$210
Price at call : $197.82 — gap to target +6%
Today : $212.38 — gap to target -1%
🎯 on DGX : no call matured yet · 📊 on Health : 47.6% · +1.3% (147 calls)
in progress (365j)
matures : Apr 8, 27
Mizuho
Feb 12, 26
▲ Outperform · 🎯$235
Price at call : $206.86 — upside +14%
Today : $212.38 — upside +11%
🎯 on DGX : 100% (4 calls matureds) · 📊 on Health : 53.8% · +4.4% (208 calls)
in progress (365j)
matures : Feb 12, 27
■ Hold neutral · not a buy · 🎯$220
Price at call : $206.86 — gap to target +6%
Today : $212.38 — gap to target +4%
🎯 on DGX : no call matured yet · 📊 on Health : 50% · +2.1% (248 calls)
in progress (365j)
matures : Feb 11, 27
UBS
Feb 11, 26
■ Neutral neutral · not a buy · 🎯$210
Price at call : $206.86 — gap to target +2%
Today : $212.38 — gap to target -1%
🎯 on DGX : no call matured yet · 📊 on Health : 52.1% · +3.4% (340 calls)
in progress (365j)
matures : Feb 11, 27
■ In-Line neutral · not a buy · 🎯$220
Price at call : $209.32 — gap to target +5%
Today : $212.38 — gap to target +4%
🎯 on DGX : no call matured yet · 📊 on Health : 47.6% · +1.3% (147 calls)
in progress (365j)
matures : Feb 11, 27
Barclays
Feb 11, 26
▲ Overweight · 🎯$225
Price at call : $209.32 — upside +7%
Today : $212.38 — upside +6%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (617 calls)
in progress (365j)
matures : Feb 11, 27
Jefferies
Feb 11, 26
▲ Buy · 🎯$220
Price at call : $209.32 — upside +5%
Today : $212.38 — upside +4%
🎯 on DGX : no call matured yet · 📊 on Health : 50.5% · +4.5% (376 calls)
in progress (365j)
matures : Feb 11, 27
Citigroup
Feb 10, 26
■ Neutral neutral · not a buy · 🎯$215
Price at call : $209.32 — gap to target +3%
Today : $212.38 — gap to target +1%
🎯 on DGX : no call matured yet · 📊 on Health : 53.4% · +2.8% (496 calls)
in progress (365j)
matures : Feb 10, 27
Piper Sandler
Oct 27, 25
■ Neutral neutral · not a buy · 🎯$200
Price at call : $178.28 — gap to target +12%
Today : $212.38 — gap to target -6%
🎯 on DGX : no call matured yet · 📊 on Health : 47% · -1.0% (313 calls)
in progress (365j)
matures : Oct 27, 26
Barclays
Oct 22, 25
■ Equal-Weight neutral · not a buy · 🎯$195
Price at call : $183.23 — gap to target +6%
Today : $212.38 — gap to target -8%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (617 calls)
in progress (365j)
matures : Oct 22, 26
■ Hold neutral · not a buy · 🎯$205
Price at call : $183.23 — gap to target +12%
Today : $212.38 — gap to target -3%
🎯 on DGX : no call matured yet · 📊 on Health : 50% · +2.1% (248 calls)
in progress (365j)
matures : Oct 22, 26
▲ Outperform · 🎯$210
Price at call : $181.17 — upside +16%
Today : $212.38 — upside -1%
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 57.1% · +6.2% (35 calls)
in progress (365j)
matures : Oct 21, 26
Jefferies
Oct 21, 25
▲ Buy · 🎯$215
Price at call : $181.17 — upside +19%
Today : $212.38 — upside +1%
🎯 on DGX : no call matured yet · 📊 on Health : 50.5% · +4.5% (376 calls)
in progress (365j)
matures : Oct 21, 26
UBS
Oct 17, 25
■ Neutral neutral · not a buy · 🎯$190
Price at call : $190.41 — gap to target -0%
Today : $212.38 — gap to target -11%
🎯 on DGX : no call matured yet · 📊 on Health : 52.1% · +3.4% (340 calls)
in progress (365j)
matures : Oct 17, 26
Mizuho
Oct 17, 25
▲ Outperform · 🎯$210
Price at call : $189.51 — upside +11%
Today : $212.38 — upside -1%
🎯 on DGX : 100% (4 calls matureds) · 📊 on Health : 53.8% · +4.4% (208 calls)
in progress (365j)
matures : Oct 17, 26
■ In-Line neutral · not a buy · 🎯$190
Price at call : $180.89 — gap to target +5%
Today : $212.38 — gap to target -11%
🎯 on DGX : no call matured yet · 📊 on Health : 47.6% · +1.3% (147 calls)
in progress (365j)
matures : Oct 8, 26
Barclays
Oct 2, 25
■ Equal-Weight neutral · not a buy · 🎯$190
Price at call : $179.33 — gap to target +6%
Today : $212.38 — gap to target -11%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (617 calls)
in progress (365j)
matures : Oct 2, 26
Baird
Aug 25, 25
■ Neutral neutral · not a buy · 🎯$194
Price at call : $180.36 — gap to target +8%
Today : $212.38 — gap to target -9%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 52.3% · +7.1% (287 calls)
in progress (365j)
matures : Aug 25, 26
UBS
Jul 23, 25
■ Neutral neutral · not a buy · 🎯$180
Price at call : $171.9 — gap to target +5%
Today : $212.38 — gap to target -15%
🎯 on DGX : no call matured yet · 📊 on Health : 52.1% · +3.4% (340 calls)
in progress (365j)
matures : Jul 23, 26
■ Hold neutral · not a buy · 🎯$192
Price at call : $171.9 — gap to target +12%
Today : $212.38 — gap to target -10%
🎯 on DGX : no call matured yet · 📊 on Health : 50% · +2.1% (248 calls)
in progress (365j)
matures : Jul 23, 26
Deutsche Bank
Jul 23, 25
■ Hold neutral · not a buy · 🎯$178
Price at call : $171.9 — gap to target +4%
Today : $212.38 — gap to target -16%
🎯 on DGX : no call matured yet · 📊 on Health : 53.3% · +4.4% (289 calls)
in progress (365j)
matures : Jul 23, 26
Jefferies
Jul 22, 25
▲ Buy · 🎯$200
Price at call : $170.48 — upside +17%
Today : $212.38 — upside -6%
🎯 on DGX : no call matured yet · 📊 on Health : 50.5% · +4.5% (376 calls)
in progress (365j)
matures : Jul 22, 26
UBS
Jul 18, 25
■ Neutral neutral · not a buy · 🎯$175
Price at call : $166.45 — gap to target +5%
Today : $212.38 — gap to target -18%
🎯 on DGX : no call matured yet · 📊 on Health : 52.1% · +3.4% (340 calls)
in progress (365j)
matures : Jul 18, 26
JP Morgan
May 6, 25
■ Neutral neutral · not a buy · 🎯$190
Price at call : $176.11 — gap to target +8%
Today : $212.38 — gap to target -11%
🎯 on DGX : no call matured yet · 📊 on Health : 53.6% · +5.2% (349 calls)
in progress (365j)
matures : May 6, 26
Piper Sandler
Apr 28, 25
■ Neutral neutral · not a buy · 🎯$200
Price at call : $178.5 — gap to target +12%
Today : $212.38 — gap to target -6%
🎯 on DGX : no call matured yet · 📊 on Health : 47% · -1.0% (313 calls)
in progress (365j)
matures : Apr 28, 26
■ Hold neutral · not a buy · 🎯$190
Price at call : $175.87 — gap to target +8%
Today : $212.38 — gap to target -11%
🎯 on DGX : no call matured yet · 📊 on Health : 50% · +2.1% (248 calls)
in progress (365j)
matures : Apr 23, 26
Barclays
Apr 23, 25
■ Equal-Weight neutral · not a buy · 🎯$185
Price at call : $173.57 — gap to target +7%
Today : $212.38 — gap to target -13%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (617 calls)
in progress (365j)
matures : Apr 23, 26
■ In-Line neutral · not a buy · 🎯$180
Price at call : $173.57 — gap to target +4%
Today : $212.38 — gap to target -15%
🎯 on DGX : no call matured yet · 📊 on Health : 47.6% · +1.3% (147 calls)
in progress (365j)
matures : Apr 23, 26
Baird
Apr 23, 25
▲ Outperform · 🎯$194
Price at call : $173.57 — upside +12%
Today : $212.38 — upside -9%
Expected +12% · Actual +15% · Reason (≥ +15%) : ✗ No
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 52.3% · +7.1% (287 calls)
+15.0%
stock +15% · XLV +8%
Mizuho
Apr 9, 25
▲ Outperform · 🎯$189
Price at call : $164.06 — upside +15%
Today : $212.38 — upside -11%
Expected +15% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (4 calls matureds) · 📊 on Health : 53.8% · +4.4% (208 calls)
+20.6%
stock +21% · XLV +8%
▲ Buy · 🎯$195
Price at call : $167.96 — upside +16%
Today : $212.38 — upside -8%
Expected +16% · Actual +18% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (1 call matured) · 📊 unranked overall
+17.9%
stock +18% · XLV +2%
Baird
Mar 20, 25
▲ Outperform · 🎯$191
Price at call : $167.11 — upside +14%
Today : $212.38 — upside -10%
Expected +14% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 52.3% · +7.1% (287 calls)
+17.1%
stock +17% · XLV -1%
Citigroup
Mar 4, 25
■ Neutral neutral · not a buy · 🎯$185
Price at call : $175.01 — gap to target +6%
Today : $212.38 — gap to target -13%
🎯 on DGX : no call matured yet · 📊 on Health : 53.4% · +2.8% (496 calls)
in progress (365j)
matures : Mar 4, 26
JP Morgan
Feb 4, 25
■ Neutral neutral · not a buy · 🎯$180
Price at call : $164.87 — gap to target +9%
Today : $212.38 — gap to target -15%
🎯 on DGX : no call matured yet · 📊 on Health : 53.6% · +5.2% (349 calls)
in progress (365j)
matures : Feb 4, 26
Mizuho
Feb 3, 25
▲ Outperform · 🎯$178
Price at call : $163.36 — upside +9%
Today : $212.38 — upside -16%
Expected +9% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (4 calls matureds) · 📊 on Health : 53.8% · +4.4% (208 calls)
+15.8%
stock +16% · XLV +6%
UBS
Feb 3, 25
■ Neutral neutral · not a buy · 🎯$170
Price at call : $163.36 — gap to target +4%
Today : $212.38 — gap to target -20%
🎯 on DGX : no call matured yet · 📊 on Health : 52.1% · +3.4% (340 calls)
in progress (365j)
matures : Feb 3, 26
■ Neutral neutral · not a buy · 🎯$180
Price at call : $163.36 — gap to target +10%
Today : $212.38 — gap to target -15%
🎯 on DGX : no call matured yet · 📊 on Health : 47% · -1.0% (313 calls)
in progress (365j)
matures : Feb 3, 26
■ Hold neutral · not a buy · 🎯$182
Price at call : $162.47 — gap to target +12%
Today : $212.38 — gap to target -14%
🎯 on DGX : no call matured yet · 📊 on Health : 50% · +2.1% (248 calls)
in progress (365j)
matures : Jan 31, 26
Barclays
Jan 31, 25
■ Equal-Weight neutral · not a buy · 🎯$175
Price at call : $163.1 — gap to target +7%
Today : $212.38 — gap to target -18%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.2% (617 calls)
in progress (365j)
matures : Jan 31, 26
▲ Outperform · 🎯$174
Price at call : $152.27 — upside +14%
Today : $212.38 — upside -18%
Expected +14% · Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 57.1% · +6.2% (35 calls)
+18.5%
stock +19% · XLV +14%
Mizuho
Dec 23, 24
▲ Outperform · 🎯$177
Price at call : $153.42 — upside +15%
Today : $212.38 — upside -17%
Expected +15% · Actual +15% · Reason (≥ +15%) : ✗ No
🎯 on DGX : 100% (4 calls matureds) · 📊 on Health : 53.8% · +4.4% (208 calls)
+14.7%
stock +15% · XLV +12%
▲ Overweight · 🎯$172
Price at call : $155.49 — upside +11%
Today : $212.38 — upside -19%
Expected +11% · Actual +15% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 51.7% · +5.3% (804 calls)
+15.2%
stock +15% · XLV +10%
▲ Buy · 🎯$182
Price at call : $152.65 — upside +19%
Today : $212.38 — upside -14%
Expected +19% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 48.6% · +2.3% (352 calls)
+20.6%
stock +21% · XLV +12%
Piper Sandler
Oct 28, 24
■ Neutral neutral · not a buy · 🎯$165
Price at call : $155.96 — gap to target +6%
Today : $212.38 — gap to target -22%
🎯 on DGX : no call matured yet · 📊 on Health : 47% · -1.0% (313 calls)
in progress (365j)
matures : Oct 28, 25
Mizuho
Oct 24, 24
▲ Outperform · 🎯$174
Price at call : $157.99 — upside +10%
Today : $212.38 — upside -18%
Expected +10% · Actual +15% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (4 calls matureds) · 📊 on Health : 53.8% · +4.4% (208 calls)
+15.3%
stock +15% · XLV -2%
UBS
Oct 23, 24
■ Neutral neutral · not a buy · 🎯$166
Price at call : $157.99 — gap to target +5%
Today : $212.38 — gap to target -22%
🎯 on DGX : no call matured yet · 📊 on Health : 52.1% · +3.4% (340 calls)
in progress (365j)
matures : Oct 23, 25
■ Market Perform neutral · not a buy · 🎯$135
Price at call : $126.2 — gap to target +7%
Today : $212.38 — gap to target -36%
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 57.1% · +6.2% (35 calls)
in progress (365j)
matures : Feb 25, 25
JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)